<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://peptidesagora.com/news/bryan-johnson-dog-wolverine-stack-veterinary</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Bryan Johnson's Dog Post Puts 'Wolverine Stack' Peptides Under Veterinary Scrutiny]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/bryan-johnson-dog-wolverine-stack-veterinary.jpg</image:loc>
      <image:title><![CDATA[Bryan Johnson's Dog Post Puts 'Wolverine Stack' Peptides Under Veterinary Scrutiny]]></image:title>
      <image:caption><![CDATA[Bryan Johnson's September 12 X post referencing the BPC-157 and TB-500 'Wolverine Stack' for his dog arrived six weeks after an FDA advisory panel recommended the peptides for human compounding, a designation that does not extend to.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/090526-fda-panel-backs-6-peptides-compounding</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Advisory Panel Overrides Staff Scientists to Back Six Peptides for 503A Compounding]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-backs-6-peptides-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Panel Overrides Staff Scientists to Back Six Peptides for 503A Compounding]]></image:title>
      <image:caption><![CDATA[A reconstituted advisory panel voted against FDA staff recommendations on six of seven peptides, opening a rulemaking path for compounds with no completed Phase 3 trials.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-peptide-reversal-glp-1-compounding-divide</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Panel Backs 6 Compounded Peptides as Agency Moves to Exclude GLP-1s]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-peptide-reversal-glp-1-compounding-divide.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Backs 6 Compounded Peptides as Agency Moves to Exclude GLP-1s]]></image:title>
      <image:caption><![CDATA[In a regulatory divergence with few precedents, the FDA's Pharmacy Compounding Advisory Committee backed BPC-157 and five other peptides for compounding eligibility despite internal scientific dissent, even as the agency moved to.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-split-verdict-peptides-glp1-compounding</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Splits Peptide Path: Panel Backs BPC-157 as GLP-1 Compounding Faces Ban]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-split-verdict-peptides-glp1-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Splits Peptide Path: Panel Backs BPC-157 as GLP-1 Compounding Faces Ban]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee narrowly backed BPC-157, TB-500, and four other peptides for small-scale compounding, even as the agency proposed a permanent exclusion of semaglutide and tirzepatide from large-scale.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/lilly-retatrutide-black-market-lawsuits</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Lilly's Six Lawsuits Target Black-Market Sellers of Unapproved Retatrutide]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/lilly-retatrutide-black-market-lawsuits.jpg</image:loc>
      <image:title><![CDATA[Lilly's Six Lawsuits Target Black-Market Sellers of Unapproved Retatrutide]]></image:title>
      <image:caption><![CDATA[By suing compounding pharmacies, medical spas, and online peptide sellers before retatrutide reaches a pharmacy shelf, Eli Lilly is asking federal courts to enforce a market boundary that does not yet exist in law.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/mounjaro-cardiovascular-indication-approval</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/mounjaro-cardiovascular-indication-approval.jpg</image:loc>
      <image:title><![CDATA[FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes]]></image:title>
      <image:caption><![CDATA[Eli Lilly's dual GIP/GLP-1 agonist Mounjaro received FDA authorization to reduce cardiovascular death, heart attack, and stroke risk in adults with type 2 diabetes, matching Novo Nordisk's earlier Ozempic indication through a different.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/oral-glp1-phase-3-12-weight-loss</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Ascletis Doses First Patient in 4,600-Person Oral GLP-1 Phase 3 Program]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oral-glp1-phase-3-12-weight-loss.jpg</image:loc>
      <image:title><![CDATA[Ascletis Doses First Patient in 4,600-Person Oral GLP-1 Phase 3 Program]]></image:title>
      <image:caption><![CDATA[The first participant received ASC30 in Ascletis' global Phase 3 program on August 30, 2026. The AURORA trials will enroll approximately 4,600 adults across the U.S. and Europe, though no interim efficacy data has been reported. The.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/tiktok-teens-unregulated-peptides-danger</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[TikTok Looksmaxxing Is Pushing Teens to Inject Unregulated Peptides]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tiktok-teens-unregulated-peptides-danger.jpg</image:loc>
      <image:title><![CDATA[TikTok Looksmaxxing Is Pushing Teens to Inject Unregulated Peptides]]></image:title>
      <image:caption><![CDATA[Teens are self-injecting peptides sold online as 'for research use only,' following tutorials on TikTok. FDA reviewers found the human safety data barely exists, and no agency has closed the regulatory gap that lets vendors ship unverified.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/veterinary-wolverine-stack-mainstream</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Viral 'Wolverine Stack' Videos Push Unapproved Peptides Into Dog Care Without Safety Data]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/veterinary-wolverine-stack-mainstream.jpg</image:loc>
      <image:title><![CDATA[Viral 'Wolverine Stack' Videos Push Unapproved Peptides Into Dog Care Without Safety Data]]></image:title>
      <image:caption><![CDATA[An eleven-year-old dog's mobility video went viral in August 2026, accelerating interest in the unapproved BPC-157 and TB-500 combination for pets. Veterinary researchers warn the evidence base consists of rodent studies and a single.]]></image:caption>
    </image:image>
  </url>
</urlset>